GGrantIndex
← Leaderboards

Linda K McLoon

University Of Minnesota Twin Cities

$8,499,341
Attributed
$10,189,217
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $860K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,189,217 · 7

By mechanism

R01$7,598,742 · 1
T32$1,087,563 · 1
R21$801,863 · 2
R03$445,500 · 1
P30$190,549 · 1
R13$65,000 · 1

Top collaborators

Most similar at University Of Minnesota Twin Cities

Same institution · by research overlap

Others in their field

Top investigators on “Adult

Research focus

AdultOperative Surgical ProceduresMuscleOculomotorEye MovementsAmblyopiaIgf1 GeneInfantPhysiologicalStrabismusChildhoodAntibodiesChildImmunotoxinsGrowth FactorOrbit MuscleOryctolagus CuniculusNonhuman PrimateMonkeysBaseLaboratoriesPreventCiliary Neurotrophic FactorDose

Grant awards (37)

Training Program in Translational Vision Sciences$119,210
T32 · FY2025 · EY · contact PI
2025 Eye Movements Gordon Research Conference and Gordon Research Seminar$65,000
R13 · FY2025 · EY · contact PI
Training Program in Translational Vision Sciences$129,797
T32 · FY2024 · EY · contact PI
Sex as a Factor in Normal Retinal Function and Schizophrenia$193,750
R21 · FY2023 · EY · contact PI
Training Program in Translational Vision Sciences$155,651
T32 · FY2023 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$479,907
R01 · FY2022 · EY · contact PI
Sex as a Factor in Normal Retinal Function and Schizophrenia$232,500
R21 · FY2022 · EY · contact PI
Training Program in Translational Vision Sciences$147,620
T32 · FY2022 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$479,909
R01 · FY2021 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$494,752
R01 · FY2020 · EY · contact PI
Training Program in Translational Vision Sciences$45,237
T32 · FY2020 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$494,752
R01 · FY2019 · EY · contact PI
Histology$190,549
P30 · FY2019 · EY · contact PI
Training Program in Translational Vision Sciences$89,289
T32 · FY2019 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$34,385
R01 · FY2019 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$536,729
R01 · FY2018 · EY · contact PI
Training Program in Translational Vision Sciences$118,070
T32 · FY2018 · EY · contact PI
Training Program in Translational Vision Sciences$142,103
T32 · FY2017 · EY · contact PI
Training Program in Translational Vision Sciences$140,586
T32 · FY2016 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$501,847
R01 · FY2015 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$501,845
R01 · FY2014 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$530,421
R01 · FY2013 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$551,588
R01 · FY2012 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$361,277
R01 · FY2011 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$376,331
R01 · FY2010 · EY · contact PI
Myogenic Potential of Extraocular Muscle Satellite Cells$186,863
R21 · FY2010 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$380,131
R01 · FY2009 · EY · contact PI
Myogenic Potential of Extraocular Muscle Satellite Cells$188,750
R21 · FY2009 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$165,482
R01 · FY2009 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$372,528
R01 · FY2008 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$392,506
R01 · FY2007 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$290,021
R01 · FY2006 · EY · contact PI
Novel Immunotoxin and IGF Therapy for Strabismus$297,000
R01 · FY2005 · EY
Novel Immunotoxin and IGF Therapy for Strabismus$357,331
R01 · FY2004 · EY
Disease and Continuous Myofiber Remodeling in EOM$148,500
R03 · FY2004 · EY
Disease and Continuous Myofiber Remodeling in EOM$148,500
R03 · FY2003 · EY
Disease and Continuous Myofiber Remodeling in EOM$148,500
R03 · FY2002 · EY